IPSEN SA S/ADR by Ipsen S.A. (IPSEY) Stock Price, Quote, News & History

Key Statistics

Open

Volume / Avg.

8.00 / 1.35K

Day Range

- - -

52 Wk Range

32.02 - 51.10

Market Cap

P/E Ratio

25.11

Dividend Yield

1.03%

Exchange

OTC

RSI

Short Interest

Days to Cover

3.55

Recent Ipsen SA News

FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo

The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability to reduce alkaline phosphatase levels, marks a significant advancement in therapies available for PBC.

Shivani Kumaresan

Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients

Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs

Vandana Singh

Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class

Friday, CymaBay Therapeutics Inc's (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC:

Vandana Singh

Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients

Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT)

Vandana Singh

What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur

On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid (OCA), don't outweigh the risks in nonalcoholic steatohepatitis (NASH)

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

1.30B

Investing Cash Flow (TTM)

-557.50M

Financing Cash Flow (TTM)

-227.70M

Free Cash Flow (TTM)

1.09B

Capital Expenditure (TTM)

-210.10M

Net Change in Cash (TTM)

537.80M

Valuation Metrics

Enterprise Value

$13.50B

PE Ratio (TTM)

25.11

PE Ratio (FWD)

11.05

PEG Ratio (TTM)

0.53

PS Ratio (TTM)

3.00

PB Ratio (TTM)

2.72

Earnings Yield % (TTM)

3.98%

Earnings Yield % (FWD)

9.05%

EV / EBITDA (TTM)

8.00

Price / EBITDA (TTM)

8.77

Price / Free Cash Flow (TTM)

11.78

Book Value / Share

$16.47

Company Debt

Total Debt

$766.00M

LT Debt

$625.60M

LT Debt Issuance (TTM)

$16.60M

LT Debt Repayment (TTM)

-$1.40M

Total Cash

$1.97B

Debt to Equity

0.19

Issuance of Debt (TTM)

$15.20M

Repayment of Debt (TTM)

-$31.30M

Key Statistics

Open

Volume / Avg.

8.00 / 1.35K

Day Range

- - -

52 Wk Range

32.02 - 51.10

Market Cap

P/E Ratio

25.11

Dividend Yield

1.03%

Exchange

OTC

RSI

Short Interest

Days to Cover

3.55

About

Sector

Health Care

Industry

Pharmaceuticals

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused o...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

IPSEY

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

IPSEY

FAQ

How do I buy IPSEN SA S/ADR by Ipsen S.A. (IPSEY) stock?

You can purchase shares of IPSEN SA S/ADR by Ipsen S.A. (OTCPK:IPSEY) through any online brokerage.

View our list of the best stock brokerages

Who are IPSEN SA S/ADR by Ipsen S.A. (IPSEY) competitors?

There are no as such competitors for IPSEN SA S/ADR by Ipsen S.A..

What is the forecast, or price target, for IPSEN SA S/ADR by Ipsen S.A. (IPSEY) stock?

There is no analysis for IPSEN SA S/ADR by Ipsen S.A. to provide a consensus price target.

What is the current price for IPSEN SA S/ADR by Ipsen S.A. (IPSEY)?

The stock price for IPSEN SA S/ADR by Ipsen S.A. (OTCPK: IPSEY) is $44.75 last updated September 17, 2026 at 10:55 AM EDT.

Does IPSEN SA S/ADR by Ipsen S.A. (IPSEY) pay a dividend?

There are no upcoming dividends for IPSEN SA S/ADR by Ipsen S.A..

When is IPSEN SA S/ADR by Ipsen S.A. (OTCPK:IPSEY) reporting earnings?

IPSEN SA S/ADR by Ipsen S.A. does not have any upcoming earnings scheduled.

Is IPSEN SA S/ADR by Ipsen S.A. (IPSEY) going to split?

There is no upcoming split for IPSEN SA S/ADR by Ipsen S.A..

What sector and industry does IPSEN SA S/ADR by Ipsen S.A. (IPSEY) operate in?

IPSEN SA S/ADR by Ipsen S.A. is in the Health Care sector and Pharmaceuticals industry. They are listed on the OTCPK.